Surface plasmon resonance binding kinetics of Alzheimer's disease amyloid β peptide-capturing and plaque-binding monoclonal antibodies

Biochemistry

Volumn 48, Issue 43, 2009, Pages 10405-10415

  Ramakrishnan, Muthu ^a   Kandimalla, Karunya K ^a,b   Wengenack, Thomas M ^a   Howell, Kyle G ^a   Poduslo, Joseph F ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER'S DISEASE; AMYLOID PEPTIDES; AMYLOID PLAQUES; ANTIGEN-BINDING SITES; ASSOCIATION AND DISSOCIATION KINETICS; ASSOCIATION RATE CONSTANTS; BASIC SCIENCE; BINDING ABILITIES; BINDING KINETICS; BIOANALYTICAL TECHNIQUES; BLOOD-BRAIN BARRIER; CLINICAL APPLICATION; DENSE CORE; ENZYMATIC DIGESTIONS; IMMUNOHISTOCHEMISTRY; KINETIC BINDING; KINETIC PROPERTIES; MONOCLONAL ANTIBODIES (MABS); POLYAMINES; RECOGNITION SITE;

AMINES; BINDING ENERGY; GLYCOPROTEINS; MONOCLONAL ANTIBODIES; PEPTIDES; PLASMONS; RATE CONSTANTS; SURFACE PLASMON RESONANCE;

BINDING SITES;

11A50 MONOCLONAL ANTIBODY; 4G8 MONOCLONAL ANTIBODY; 6E10 MONOCLONAL ANTIBODY; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-40]; EPITOPE; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G4.1; MONOCLONAL ANTIBODY; POLYAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING KINETICS; BINDING SITE; BLOOD BRAIN BARRIER; BRAIN SLICE; CONTROLLED STUDY; DISSOCIATION; DRUG BINDING SITE; DRUG PENETRATION; DRUG PROTEIN BINDING; ENZYME DEGRADATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENILE PLAQUE; SURFACE PLASMON RESONANCE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES, MONOCLONAL; EPITOPE MAPPING; IMMUNOHISTOCHEMISTRY; KINETICS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTEIN BINDING; SURFACE PLASMON RESONANCE;

EID: 70350513003     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi900523q     Document Type: Article

References (30)

1. Selkoe, D. J. (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol. Rev. 81, 741-766.
2. Paravastu, A. K., Leapman, R. D., Yau, W. M., and Tycko, R. (2008) Molecular structural basis for polymorphism in Alzheimer's β-amyloid fibrils. Proc. Natl. Acad. Sci. U.S.A. 105, 18349-18354.
3. Petkova, A. T., Leapman, R. D., Guo, Z., Yau, W. M., Mattson, M. P., and Tycko, R. (2005) Self-propagating, molecular-level polymorphism in Alzheimer's β-amyloid fibrils. Science 307, 262-265. (Pubitemid 40116242)
4. Tycko, R. (2006) Molecular structure of amyloid fibrils: Insights from solid-state NMR. Q. Rev. Biophys. 39, 1-55.
5. Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., Regan, C. M., Walsh, D. M., Sabatini, B. L., and Selkoe, D. J. (2008) Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842.
6. Lesne, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., and Ashe, K. H. (2006) A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352-357.
7. Bard, F., Cannon, C., Barbour, R., Burke, R. L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Lieberburg, I., Motter, R., Nguyen, M., Soriano, F., Vasquez, N., Weiss, K., Welch, B., Seubert, P., Schenk, D., and Yednock, T. (2000) Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat. Med. 6, 916-919.
8. Foster, J. K., Verdile, G., Bates, K. A., and Martins, R. N. (2008) Immunization in Alzheimer's disease: Naive hope or realistic clinical potential? Mol. Psychiatry 14, 239-251.
9. Nitsch, R. M., and Hock, C. (2008) Targeting β-amyloid pathology in Alzheimer's disease with Aβ immunotherapy. Neurotherapeutics 5, 415-420. (Pubitemid 351952496)
10. DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J. C., Paul, S. M., and Holtzman, D. M. (2001) Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98, 8850-8855.
11. Seubert, P., Barbour, R., Khan, K., Motter, R., Tang, P., Kholodenko, D., Kling, K., Schenk, D., Johnson-Wood, K., Schroeter, S., Gill, D., Jacobsen, J. S., Pangalos, M., Basi, G., and Games, D. (2008) Antibody capture of soluble Aβ does not reduce cortical Aβ amyloidosis in the PDAPP mouse. Neurodegener. Dis. 5, 65-71.
12. Ramakrishnan, M., Wengenack, T. M., Kandimalla, K. K., Curran, G. L., Gilles, E. J., Ramirez-Alvarado, M., Lin, J., Garwood, M., Jack, C. R., Jr., and Poduslo, J. F. (2008) Selective contrast enhancement of individual Alzheimer's disease amyloid plaques using a polyamine and Gd-DOTA conjugated antibody fragment against fibrillar Aβ42 for magnetic resonance molecular imaging. Pharm. Res. 25, 1861-1872.
13. Poduslo, J. F., Ramakrishnan, M., Holasek, S. S., Ramirez-Alvarado, M., Kandimalla, K. K., Gilles, E. J., Curran, G. L., and Wengenack, T. M. (2007) In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. J. Neurochem. 102, 420-433.
14. Poduslo, J. F., Curran, G. L., and Berg, C. T. (1994) Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc. Natl. Acad. Sci. U.S.A. 91, 5705-5709.
15. Abdullah, L., Paris, D., Luis, C., Quadros, A., Parrish, J., Valdes, L., Keegan, A. P., Mathura, V., Crawford, F., and Mullan, M. (2007) The influence of diagnosis, intra- and inter-person variability on serum and plasma Aβ levels. Neurosci. Lett. 428, 53-58.
16. Ertekin-Taner, N., Younkin, L. H., Yager, D. M., Parfitt, F., Baker, M. C., Asthana, S., Hutton, M. L., Younkin, S. G., and Graff- Radford, N. R. (2008) Plasma amyloid β protein is elevated in late-onset Alzheimer's disease families. Neurology 70, 596-606.
17. Ringman, J. M., Younkin, S. G., Pratico, D., Seltzer, W., Cole, G. M., Geschwind, D. H., Rodriguez-Agudelo, Y., Schaffer, B., Fein, J., Sokolow, S., Rosario, E. R., Gylys, K. H., Varpetian, A., Medina, L. D., and Cummings, J. L. (2008) Biochemical markers in persons with preclinical familial Alzheimer's disease. Neurology 71, 85-92.
18. Agyare, E. K., Curran, G. L., Ramakrishnan, M., Yu, C. C., Poduslo, J. F., and Kandimalla, K. K. (2008) Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy. Pharm. Res. 25, 2674-2684.
19. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., and Cole, G. (1996) Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99-102.
20. Wengenack, T. M., Whelan, S., Curran, G. L., Duff, K. E., and Poduslo, J. F. (2000) Quantitative histological analysis of amyloid deposition in Alzheimer's double transgenic mouse brain. Neuroscience 101, 939-944. (Pubitemid 30952917)
21. Bitan, G., and Teplow, D. B. (2005) Preparation of aggregate-free, low molecular weight amyloid-β for assembly and toxicity assays. Methods Mol. Biol. 299, 3-9.
22. Nichols, M. R., Moss, M. A., Reed, D. K., Lin, W. L., Mukhopadhyay, R., Hoh, J. H., and Rosenberry, T. L. (2002) Growth of β-amyloid- (1-40) protofibrils by monomer elongation and lateral association. Characterization of distinct products by light scattering and atomic force microscopy. Biochemistry 41, 6115-6127.
23. Langmuir, I. (1918) The adsorption of gases on plane surfaces of glass, mica and platinum. J. Am. Chem. Soc. 40, 1361-1404.
24. Tsurushita, N., and Vasquez, M. J., US Patent No. 7,318,923 B2.
25. Kayed, R., Head, E., Sarsoza, F., Saing, T., Cotman, C. W., Necula, M., Margol, L., Wu, J., Breydo, L., Thompson, J. L., Rasool, S., Gurlo, T., Butler, P., and Glabe, C. G. (2007) Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegener. 2, 18.
26. Davies, J., Tang, Y., and Watkins, J. D. US Patent No. US 2006/ 0110388 A1.
27. Rak, M., Del Bigio, M. R., Mai, S., Westaway, D., and Gough, K. (2007) Dense-core and diffuse Aβ plaques in TgCRND8 mice studied with synchrotron FTIR microspectroscopy. Biopolymers 87, 207-217. (Pubitemid 350075351)
28. Thakker, D. R., Weatherspoon, M. R., Harrison, J., Keene, T. E., Lane, D. S., Kaemmerer, W. F., Stewart, G. R., and Shafer, L. L. (2009) Intracerebroventricular amyloid-β antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc. Natl. Acad. Sci. U.S.A. 106, 4501-4506.
29. Lee, M., Bard, F., Johnson-Wood, K., Lee, C., Hu, K., Griffith, S. G., Black, R. S., Schenk, D., and Seubert, P. (2005) Aβ42 immunization in Alzheimer's disease generates Aβ N-terminal antibodies. Ann. Neurol. 58, 430-435.
30. Gray, A. J., Sakaguchi, G., Shiratori, C., Becker, A. G., LaFrancois, J., Aisen, P. S., Duff, K., and Matsuoka, Y. (2007) Antibody against C-terminal Aβ selectively elevates plasma Aβ. NeuroReport 18, 293-296. (Pubitemid 46303784)